Paper40769005
Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy.
Song F and 7 others. Drug Resist Updat, 2025. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy. Papers, record 40769005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40769005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Molecular Targeted Therapy | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Tumor Microenvironment | |
| Signal Transduction | |
| Mutation | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Precision Medicine |
Source PubMed
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941734 | Genetic and Immunologic Interactions Driving STAT3 Signaling and Macrophage Polarization in Acute Myeloid Leukemia. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941734 | PubMed |
| 42929838 | LEDGF/p75 Mediates Chemoresistance in Leukemia in a Context Dependent Manner. | Cells | 2026 | https://conductscience.org/library/papers/42929838 | PubMed |
| 42866821 | Mechanistic investigation of the crosstalk between hepatic ischemia-reperfusion injury and intestinal microbiota. | Transl Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42866821 | PubMed |
| 42496998 | Leveraging Immunotherapy in Acute Myeloid Leukemia Treatment: Opportunities and Challenges. | Technol Cancer Res Treat | 2026 | https://conductscience.org/library/papers/42496998 | PubMed |
| 42469871 | TRIM24 stabilizes the p110 CUX1 oncoprotein via USP10 to promote chemoresistance in acute myeloid leukemia. | J Transl Med | 2026 | https://conductscience.org/library/papers/42469871 | PubMed |
| 42452347 | Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin. | J Clin Med | 2026 | https://conductscience.org/library/papers/42452347 | PubMed |
| 42201477 | Bioinformatics analysis and preliminary clinical validation of ITGA9 and NPTX2 as prognosis-related genes in acute myeloid leukemia. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42201477 | PubMed |
| 42199454 | Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia. | Blood Lymphat Cancer | 2026 | https://conductscience.org/library/papers/42199454 | PubMed |
| 41786997 | From mechanism to clinic: a panoramic perspective on targeting HMOX1 to overcome drug resistance. | J Cancer Res Clin Oncol | 2026 | https://conductscience.org/library/papers/41786997 | PubMed |
| 41772642 | Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies. | J Transl Med | 2026 | https://conductscience.org/library/papers/41772642 | PubMed |
| 41754865 | Frontiers in Antibody-Drug Conjugates: Mechanisms, Design Innovations, and Clinical Applications in Targeted Cancer Therapy. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41754865 | PubMed |
| 41224963 | HPCAL1 as a novel prognostic biomarker in acute myeloid leukemia and its correlation with immune infiltrates. | Sci Rep | 2025 | https://conductscience.org/library/papers/41224963 | PubMed |
| 41104889 | Targeting cell death pathways in acute myeloid leukemia: Molecular mechanisms and clinical implications (Review). | Oncol Rep | 2025 | https://conductscience.org/library/papers/41104889 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| CD33 | 945 | PubTator's text mining | https://conductscience.org/library/genes/945 | NCBI Gene |
| CD47 | 961 | PubTator's text mining | https://conductscience.org/library/genes/961 | NCBI Gene |
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 | NCBI Gene |
| IDH1 | 3417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| IDH2 | 3418 | PubTator's text mining | https://conductscience.org/library/genes/3418 | NCBI Gene |
| IL3RA | 3563 | PubTator's text mining | https://conductscience.org/library/genes/3563 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40769005
GET https://conductscience.org/api/papers/v1/40769005/authors